image credit: Unsplash

FDA halts use of GlaxoSmithKline and Vir’s COVID-19 drug Xevudy in 8 northeast states

March 28, 2022

With new strains of the coronavirus showing their elusiveness and pushing more antibody treatments toward irrelevance, is there danger of an over-reliance on COVID-19 oral antivirals, especially Pfizer’s Paxlovid?

Friday, the U.S. paused the distribution of GlaxoSmithKline and Vir Biotechnology’s antibody drug Xevudy in the northeast, where the omicron subvariant BA.2 now accounts for more than half of new infections.

The states included in the directive are Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Rhode Island and Vermont. In addition, Xevudy’s use will be halted in Puerto Rico and the Virgin Islands.

Read More on FiercePharma